CSL shares down 5% after post-heart attack drug disappoints in late-stage test
CSL’s cholesterol efflux enhancer failed to prevent repeat cardiac events in a Phase III study that recruited patients who had a recent myocardial infarction, prompting a drop in the company’s share price. The Phase III AEGIS-II trial tested the drug, CSL112, against placebo in more than 18,200 patients in the